Document is current
Any future updates will be listed below
-
Authors
Hussein, Humaira
Abrams, Keith R.
Gray, Laura J.
Anwer, Sumayya
Dias, Sofia
Bujkiewicz, Sylwia
-
Funding
Funding for this research was provided by:
Medical Research Council (MR/R025223/1, MR/R025223/1, MR/R025223/1, MR/R025223/1, MR/R025223/1, MR/R025223/1)
- License Information
-
More Information
Article History
Received: 21 December 2022
Accepted: 14 April 2023
First Online: 22 April 2023
Declarations
:
: Not applicable.
: Not applicable.
: KRA is a member of the National Institute for Health and Care Excellence (NICE) Diagnostics Advisory Committee, the NICE Decision and Technical Support Units, and is a National Institute for Health Research (NIHR) Senior Investigator Emeritus [NF-SI-0512-10159]. He has served as a paid consultant, providing unrelated methodological and strategic advice, to the pharmaceutical and life sciences industry generally, as well as to DHSC/NICE, and has received unrelated research funding from Association of the British Pharmaceutical Industry (ABPI), European Federation of Pharmaceutical Industries & Associations (EFPIA), Pfizer, Sanofi and Swiss Precision Diagnostics/Clearblue. He has also received course fees from the Association of the British Pharmaceutical Industry (ABPI) and is a Partner and Director of Visible Analytics Limited, a health technology assessment consultancy company.SD has received course fees from the ABPI.SB is a member of the NICE Decision Support Unit. She has served as a paid consultant, providing methodological advice, to NICE, Roche, RTI Health Solutions and IQVIA, received payments for educational events from Roche and has received research funding from European Federation of Pharmaceutical Industries & Associations (EEPIA) and Johnson & Johnson.All other authors have no competing interest to declare.
